Phaseline

Companies › Pyxis Oncology

Pyxis Oncology: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PYX-201
Antibody-drug conjugate
–Phase 1Solid Tumor; Advanced Solid TumorsApr 2027
PYX-106–Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05718557PYX-106Phase 1Solid TumorOncologyMay 2026
NCT05720117PYX-201Phase 1Solid TumorOncologyApr 2027
NCT06795412PYX-201Phase 1Advanced Solid TumorsOncologyDec 2027

From the company's SEC filings

Cash and short-term investments of $56m on 2026-09-30; operating cash outflow about $81m a year; runway about 8 months at that burn, to Jun 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.